ALK-Abello A/S
https://www.alk.net/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ALK-Abello A/S
Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Merck Extends Timeline On Acceleron Deal, Still Expects Q4 Close
Merck said it is giving the FTC more time to review the acquisition, but the shift also gives the company leeway to convince any reluctant Acceleron shareholders to trade their shares for cash.
Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
Company Information
- Industry
- In Vitro Diagnostics
-
Pharmaceuticals
- Drug Delivery
- Vaccines
- Other Names / Subsidiaries
-
- ALK-Abelló
- Allergy Laboratories, Inc.
- Crystal Laboratory LLC